PharmaZell Group is pleased to announce that the US Food and Drug Administration has granted approval of Breckenridge Pharmaceutical, Inc. Abbreviated New Drug Application for Teriflunomide 7mg & 14mg Tablets (generic for Aubagio®) on September 24, 2021. This product was developed by PharmaZell in collaboration with Breckenridge. The received FDA approval will allow Breckenridge, based
Moving forward in plan. Reactors and Centrifuges are in place…
We are pleased to announce that PharmaZell(India)Private Limited has been awarded EcoVadis Silver Medal in Recognition for Sustainability Performance. This Recognition places our company among the top 25 percent of companies assessed by EcoVadis.
New expansion of fully automated and dedicated Production facility for Mesalamine has picked up its momentum at Visakhapatnam site. It is targeted to start the production in October-2021. Impact of COVID-19 lead to few disturbances for 2-3 weeks, however there are adeuqate buffer time in plan to mitigate potential delays. Majority of the equipment are
20 April 2021, the PharmaZell Group one on Europe’s leading manufacturer of active ingredients, is pleased to announce its production site FarmaBios SpA (in Gropello/Italy) has received validation from the European Commission (“EC”), and European Food Safety Authority (“EFSA”) for the dossier on synthetic CBD as a Novel Food.
CEO Dr. Oliver Bolzern visited the Visakhapatnam site in February. He appreciated the various measures and efforts taken during COVID pandemic which has helped to restrict any potential disturbance in the operations.
We are pleased to announce that the activities on synthetic CBD at our Farmabios site are progressing smoothly. The API is produced at a commercial batch size using a THC-free route, allowing us to satisfy high customer demands. As extension to the existing EU- and US-DMF for our pharmaceutical grade CBD, a Novel Food dossier